Αρχική World News Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer

Encorafenib, Cetuximab Combination Approved for Metastatic Colorectal Cancer

, by NCI Staff

Colon Cancer Attacking Cell

Some people with metastatic colorectal cancer have a new treatment option, with FDA’s recent approval of the targeted drug encorafenib (Braftovi), in combination with another targeted therapy, cetuximab (Erbitux).

Credit: iStock

The Food and Drug Administration (FDA) has approved encorafenib (Braftovi) for the treatment of some patients with colorectal cancer. The approval covers the use of encorafenib in combination with cetuximab (Erbitux) in adults with metastatic colorectal cancer whose tumors have a specific mutation in the BRAF gene, called V600E, and who have already undergone at least one prior treatment regimen. 

Both drugs are targeted therapies. Cetuximab, which targets a protein known as EGFR, has already been approved to treat some patients with colorectal cancer. Until this new approval, encorafenib, which targets the BRAF protein, was only approved to treat patients with melanoma whose tumors had BRAF mutations. 

The new approval was based on findings from a large phase 3 clinical trial, BEACON CRC, that was sponsored by the drug’s manufacturer, Pfizer. 

The V600E mutation in the BRAF gene is found in about 10% of metastatic colorectal cancers and is associated with especially poor outcomes. “It’s definitely a group of patients who do not do well with the available therapies, so the availability of this drug combination is definitely a big step forward,” said Carmen Allegra, M.D., special advisor on gastrointestinal cancer therapeutics in NCI’s Division of Cancer Treatment and Diagnosis

BRAF inhibitors alone have been found to be of limited benefit for patients with BRAF-mutant colorectal cancer, Dr. Allegra explained. “It’s clear that if you just inhibit BRAF, the primary driver of the cancer, the cancer figures out a way around that.”

The BEACON CRC trial was designed to test whether combining targeted therapies to simultaneously block multiple components of the BRAF signaling pathway could improve outcomes in patients with metastatic BRAF-mutant colorectal cancer.

The trial investigators compared both a three-drug combination of encorafenib, cetuximab, and binimetinib (Mektovi) and a two-drug combination of encorafenib and cetuximab with standard chemotherapy plus cetuximab (the control arm). Both combinations were superior to standard treatment, and the two-drug combination was just as effective as the three-drug regimen.

Patients who received encorafenib and cetuximab had a median overall survival of 8.4 months compared with 5.4 months for patients in the control arm. Also, more patients who received the two-drug combination had reductions in the size of their tumors (a tumor response) than patients in the control arm: 20% versus 2%. 

The trial “is teaching us something about how to use these targeted therapies,” Dr. Allegra said.

The most common severe side effects in patients treated with encorafenib and cetuximab included fatigue and weakness. Other common reactions included nausea, rash, and diarrhea. 

Further details on encorafenib and cetuximab and the BEACON CRC trial were described in this November 2019 Cancer Currents article.



Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like

Διαβαστε Επίσης


ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

FDA Approves Companion Diagnostic to Identify NTRK Fusions in Solid Tumours for Larotrectinib

On 23 October 2020, the US Food and Drug Administration (FDA) approved the next-generation sequencing (NGS)-based FoundationOne CDx test (Foundation Medicine, Inc.) as a...

An existing blood test for ovarian cancer has been re-evaluated. The results are in.

Ovarian cancer is the sixth most common cancer in women in the UK, with about 7,400 new cases every year. This number equates to...

Teacher Is Glad She Asked for More Testing After Mammogram Failed to Detect Her Breast Cancer

Martha Gray has a long history of breast cancer in her family, so she knows that she needs to take her mammograms seriously every...

How to Stay Healthy After Cancer

I try to pack helpful advice into every follow-up visit I have with patients, focusing on little tips that help foster healthy lifestyles. This...

Feasibility and Preliminary Efficacy Results of the Beat AML Study

Precision medicine in acute myeloid leukaemia (AML) is feasible in terms of providing cytogenetic and mutational data within 7 days, allowing their rapid incorporation into...

Woman Battles Breast Cancer While Pregnant, Delivers Healthy Baby Boy

When she was six months pregnant, Desiree Doughty noticed that something seemed to be wrong with her breasts. “I noticed that one of my breasts...